Capital Research Global Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Research Global Investors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$78.7M	Sell	101,891 -1,445	-1%	-$1.11M	0.01%	326
2025 Q4	$79.8M	Sell	103,336 -2,413	-2%	-$1.64M	0.01%	322
2025 Q3	$59.5M	Buy	105,749 +3,635	+4%	+$2.06M	0.01%	340
2025 Q2	$53.6M	Buy	102,114 +20,001	+24%	+$11.2M	0.01%	341
2025 Q1	$52.1M	Buy	+82,113	New	+$56.5M	0.01%	353
2024 Q4	–	Sell	-644,868	Closed	-$678M	–	458
2024 Q3	$678M	Buy	644,868 +86,081	+15%	+$95.8M	0.14%	124
2024 Q2	$587M	Buy	558,787 +164,605	+42%	+$160M	0.13%	132
2024 Q1	$379M	Sell	394,182 -12,222	-3%	-$11.6M	0.09%	168
2023 Q4	$357M	Sell	406,404 -6,985	-2%	-$5.75M	0.09%	177
2023 Q3	$340M	Sell	413,389 -7,655	-2%	-$6.02M	0.09%	181
2023 Q2	$303M	Buy	421,044 +4	+0%	+$3.08K	0.08%	184
2023 Q1	$346M	Buy	+421,040	New	+$318M	0.1%	171

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Research Global Investors's REGN Position: Q1 2026 in Review

Capital Research Global Investors reduced its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, selling an estimated $1.11M and leaving 101,891 shares worth $78.7M. The position accounts for 0.01% of the portfolio, ranked #326.

Capital Research Global Investors first reported a position in REGN in Q1 2023 and has held it in 12 quarters since. The position peaked at $678M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Capital Research Global Investors held 101,891 shares of Regeneron Pharmaceuticals worth $78.7M as of Q1 2026.
Capital Research Global Investors sold 1,445 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
Regeneron Pharmaceuticals made up 0.01% of Capital Research Global Investors's portfolio in Q1 2026, its #326 holding.
Capital Research Global Investors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Capital Research Global Investors's Regeneron Pharmaceuticals position peaked at $678M in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.